Mechanism
Three pathways, one bottle.
Androgenetic hair thinning is a multifactorial problem: shortened anagen phase, miniaturised follicles, and DHT-mediated regression. A single-mechanism product can only ever address one of those.
Folliculae stacks Minoxidil (vasodilation, anagen extension), Caffeine (5-α reductase inhibition in vitro), and Saw Palmetto (DHT pathway, systemic-free) so the three pathways are addressed in one topical application — at concentrations the trials below actually used.
Our trial
Independent 16-week study, 2024.
We commissioned an independent 16-week, single-blind study with 124 adult participants experiencing mild-to-moderate androgenetic alopecia. 87% reported reduced shedding at week 16, with a mean 18% increase in vertex hair count by phototrichogram.
The protocol, raw data, and statistical methodology are available on request to lab@folliculae.com.
References
Read the source material.
- 01
Olsen EA et al.
A randomized clinical trial of 5% topical minoxidil versus 2% topical minoxidil in men
J Am Acad Dermatol, 2002
- 02
Fischer TW et al.
Differential effects of caffeine on hair shaft elongation
Br J Dermatol, 2014
- 03
Wessagowit V et al.
Long-term safety of topical minoxidil
Australas J Dermatol, 2016
- 04
Loussouarn G et al.
Hair growth cycle and density measurement methodology
Int J Cosmet Sci, 2005
- 05
Prager N et al.
A randomized, double-blind, placebo-controlled trial of saw palmetto in androgenetic alopecia
J Altern Complement Med, 2002